Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Completed 10Terminated 2Withdrawn 1

Sponsor Class

NIH 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other solid neoplasm 1Lymphoid 1

Conditions

Unspecified Adult Solid Tumor, Protocol Specific 1Lymphoma, Large-Cell, Anaplastic 1

Interventions

Cyclophosphamide 389Carboplatin 343Gemcitabine 331pembrolizumab 328Cisplatin 327Paclitaxel 294Radiotherapy 291Docetaxel 285Bevacizumab 249Rituximab 233Capecitabine 221Nivolumab 218Dexamethasone 205Fluorouracil 189fludarabine 177Oxaliplatin 177Pemetrexed 153Doxorubicin 152Irinotecan 147Etoposide 144Leucovorin 143Cytarabine 133Bortezomib 129fludarabine phosphate 128Cetuximab 126Lenalidomide 125Filgrastim 119Erlotinib Hydrochloride 119Temozolomide 111Radiosurgery 110

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Terminated × Interventional × indolepropanol phosphate × Clear all
NCT00354107 2018-03-14

Ifosfamide, Carboplatin, Etoposide, and SGN-30 in Treating Young Patients With Recurrent Anaplastic Large Cell Lymphoma

National Cancer Institute (NCI)

Phase 1/2 Terminated
5 enrolled 9 charts
Lymphoid

Lymphoma, Large-Cell, Anaplastic

NCT00086970 2013-01-24

Ifosfamide With or Without O(6)-Benzylguanine in Treating Patients With Unresectable, Metastatic Solid Tumors

National Cancer Institute (NCI)

Phase 1 Terminated
32 enrolled
Other solid neoplasm

Unspecified Adult Solid Tumor, Protocol Specific

Data powered by HemOnc (CC BY 4.0) Colophon âš¡